Last reviewed · How we verify
Safety and Feasibility of a Malaria Transmission Model in Semi-immune Kenyan Adults Using Plasmodium Falciparum Sporozoites (CHMI-TransMod)
This is to develop a model to test the efficacy of vaccines and/or drugs designed to block transmission of malaria to mosquitoes and to identify the targets of transmission-blocking immunity to malaria.
Details
| Lead sponsor | University of Oxford |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | SUSPENDED |
| Enrolment | 44 |
| Start date | 2022-08-22 |
| Completion | 2026-08 |
Conditions
- Malaria,Falciparum
Interventions
- PfSPZ Challenge
- Sulfadoxine-Pyrimethamine
- Piperaquine
- Artemether lumefantrine
- Primaquine
Primary outcomes
- Safety and optimisation of sporozoite dose for infections success in individuals with moderate-high malaria exposure — Up to 42 days post infection with PfSPZ challenge
Magnitude and frequency of adverse events in the study groups - Prevalence of gametocytes — Up to 42 days post infection with PfSPZ challenge
Prevalence of gametocytes as determined by qRT-PCR
Countries
Kenya